diffuse glioma, H3 G34 mutant
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0080880
Name diffuse glioma, H3 G34 mutant
Definition A histone mutated tumor that has_material_basis_in mutations in codon 34 of the H3 histone family 3A protein.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer high grade glioma histone mutated tumor diffuse glioma, H3 G34 mutant

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04908176 Phase I Avapritinib + Midazolam A Drug-drug Interaction Study of Avapritinib and Midazolam Completed USA 0
NCT05429502 Phase Ib/II Ribociclib + Temozolomide + Topotecan Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors Terminated USA | ITA | GBR | DEU 0
NCT05457959 Phase I Nivolumab + Poly ICLC Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Poly ICLC DC tumor cell lysate vaccine + Ipilimumab + Nivolumab + Poly ICLC DC tumor cell lysate vaccine + Nivolumab + Poly ICLC Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Withdrawn USA 0
NCT05843253 Phase II Ribociclib + Temozolomide Everolimus + Ribociclib Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant Recruiting USA | NLD | GBR | DEU | CAN | AUS 0
NCT06342908 Phase I Neoantigen-targeted ppDC Poly ICLC A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma Recruiting USA 0
NCT06413706 Phase II Abemaciclib + Temozolomide Temozolomide A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy Recruiting USA | ROU | NLD | ITA | FRA | ESP | DNK | BEL | AUS 1
NCT06630260 Phase Ib/II Defactinib + RO5126766 + Temozolomide Defactinib + RO5126766 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (5G-RUBY) Recruiting GBR 0
NCT06632236 Phase I Amivantamab-vmjw 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) Recruiting GBR 0
NCT06894979 Phase I AZD1390 Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma Recruiting USA 0
NCT06896110 Phase I Azacitidine + Nivolumab Intrathecal Azacitidine and Nivolumab in Patients with Recurrent High-grade Glioma Enrolling by invitation USA 0
NCT06914479 Phase I AdV-Flt3L + AdV-HSV1-TK + Valganciclovir Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors Not yet recruiting USA 0
NCT07223034 Phase I lutetium Lu 177 vipivotide tetraxetan + Temozolomide A Study of 177Lu-PSMA-617 in People With Gliomas Recruiting USA 0